Cellectar Biosciences, Inc.
CLRB
$3.17
-$0.09-2.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -124.81% | 69.70% | -492.55% | 75.21% | 70.11% |
| Total Depreciation and Amortization | -27.84% | -23.76% | -15.76% | -36.38% | -2.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 103.39% | -90.86% | 100.71% | -94.03% | -154.26% |
| Change in Net Operating Assets | 1,061.48% | -107.93% | 111.80% | -67.82% | -104.02% |
| Cash from Operations | 60.20% | 53.36% | 63.83% | 29.77% | -13.73% |
| Capital Expenditure | 90.38% | -- | -- | -- | 77.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 90.38% | -- | -- | -- | 77.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -67.04% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -67.04% | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.85% | -81.97% | 79.78% | -130.80% | -16.49% |